Skip to content

US · ESTA · MEDICAL - DEVICES

Establishment Labs Holdings Inc. (ESTA) intrinsic value and stock valuation

$69.14as of 2026-11-21 · Mkt cap 2.28B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Establishment Labs Holdings Inc. DCF and intrinsic value

InvestorsCraft values ESTA with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from ESTA’s statements →

Establishment Labs Holdings Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Austin, TX 78758 establishmentlabs.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$211.1M+20% 5y CAGRd
20162025
Net income
-$-51.06M
20162025
Free cash flow
-$-57.61M
20162025
Total equity
$23.6M-20.7% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$211.1M$166M$165.2M$161.7M$126.7M
Operating income-$-39.01M-$-49.99M-$-65.03M-$-39.66M-$-25.14M
Net income-$-51.06M-$-84.6M-$-78.5M-$-75.21M-$-41.14M
EPSd-$-1.72M-$-3M-$-3.07M-$-3.07M-$-1.72M
Operating cash flow-$-50.89M-$-58.52M-$-88.51M-$-52.17M-$-27.53M
Capital expenditure-$-6.72M-$-15.56M-$-24.55M-$-34.27M-$-6.73M
Free cash flow-$-57.61M-$-74.08M-$-113.06M-$-86.43M-$-34.26M
Total assets$357.2M$346.8M$268.6M$211.1M$139.5M
Total debt$264.5M$225.3M$192.2M$179.4M$54.2M
Net debt$188.9M$135M$152.2M$113M$790K
Total equity$23.6M$53.1M$18.4M-$-8.19M$50.7M
Cash and short-term investments$75.6M$90.4M$40M$66.4M$53.4M
Income statement
20252024202320222021
Revenue$211.1M$166M$165.2M$161.7M$126.7M
Cost of revenue$64.8M$56.5M$58.2M$55.1M$41.3M
Gross profit$146.3M$109.5M$107M$106.6M$85.4M
Research and development expenses$20.3M$19.7M$26.4M$20.3M$18.3M
Selling, general and administrative expenses$165.1M$139.8M$145.6M$126M$92.2M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$185.3M$159.5M$172M$146.3M$110.5M
Cost and expenses$250.1M$216M$230.2M$201.4M$151.8M
Interest income$420K$1.48M$1.02M$90K$20K
Interest expense$25.3M$20.8M$15.4M$11.8M$9.06M
Depreciation and amortization$10.5M$7.58M$4.88M$4.17M$4.11M
Ebitda-$-22.29M-$-56.22M-$-58.31M-$-56.9M-$-26.54M
Operating income-$-39.01M-$-49.99M-$-65.03M-$-39.66M-$-25.14M
Total other income/expenses, net-$-19.01M-$-34.64M-$-13.56M-$-33.17M-$-14.57M
Income before tax-$-58.02M-$-84.63M-$-78.58M-$-72.82M-$-39.71M
Income tax expense-$-6.96M-$-30K-$-80K$2.38M$1.43M
Net income-$-51.06M-$-84.6M-$-78.5M-$-75.21M-$-41.14M
Weighted average shares outstanding$29.6M$28.2M$25.6M$24.5M$24M
Weighted average diluted shares outstanding$29.6M$28.2M$25.6M$24.5M$24M
Balance sheet
20252024202320222021
Cash and short-term investments$75.6M$90.4M$40M$66.4M$53.4M
Net receivables$77.5M$65M$46.9M$35.4M$24.4M
Inventory$85.6M$78.8M$79.5M$36.6M$28.4M
Total current assets$249.9M$243M$174.9M$149.9M$113.3M
Property, plant and equipment, net$80M$83.6M$80.6M$54.8M$20.9M
Goodwill and intangible assets$11.2M$12.9M$8.45M$5.07M$4.84M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$107.2M$103.8M$93.7M$61.2M$26.3M
Total assets$357.2M$346.8M$268.6M$211.1M$139.5M
Accounts payable$43.1M$44.8M$41.6M$20M$14.5M
Short-term debt$14.1M$1.51M$770K$690K$400K
Deferred revenue$1.21M$1.75M$1.84M$1.69M$770K
Total current liabilities$82.1M$68.3M$57.2M$39M$31.9M
Long-term debt$250.3M$223.8M$191.5M$178.7M$53.8M
Deferred revenue, non-current$1.14M$1.12M$1.5M$1.67M$2.39M
Total non-current liabilities$251.5M$225.5M$193.1M$180.3M$56.9M
Capital lease obligations$4.53M$5.72M$3.48M$3.89M$2.3M
Total liabilities$333.6M$293.7M$250.3M$219.3M$88.8M
Common stock$433.4M$420.4M$315.6M$223.6M$219.7M
Retained earnings-$-495.76M-$-444.69M-$-360.1M-$-281.59M-$-206.38M
Accumulated other comprehensive income (loss)$1.16M$3.29M$1.96M$2.71M$3.66M
Total equity$23.6M$53.1M$18.4M-$-8.19M$50.7M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$264.5M$225.3M$192.2M$179.4M$54.2M
Net debt$188.9M$135M$152.2M$113M$790K
Cash flow statement
20252024202320222021
Net income-$-51.06M-$-84.6M-$-78.5M-$-75.21M-$-41.14M
Depreciation and amortization-$-9.56M$7.58M$4.88M$4.34M$4.12M
Stock-based compensation-$-11.41M$15.4M$14.9M$13.4M$10.4M
Change in working capital-$-13.17M-$-15.5M-$-34.13M-$-21.54M-$-6.44M
Accounts receivable-$-11.47M-$-26.28M-$-11.56M-$-12.33M-$-6.7M
Inventory-$-7.06M-$-470K-$-42.23M-$-10.9M-$-7.64M
Accounts payable-$-2.3M$6.67M$19M$4.38M$4.96M
Net cash provided by operating activities-$-50.89M-$-58.52M-$-88.51M-$-52.17M-$-27.53M
Investments in property, plant and equipment-$-6.05M-$-6.11M-$-7.91M-$-34.27M-$-6.73M
Acquisitions, net-$-310K-$-50K$0.00$0.00$0.00
Net cash used for investing activities-$-7.03M-$-15.61M-$-24.55M-$-34.79M-$-7.16M
Common stock issued$7.59M$99.5M$84.5M$3.87M$4.58M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$40.4M$125.9M$86.2M$100.3M$4.05M
Net change in cash-$-14.78M$50.3M-$-26.32M$12.9M-$-31.11M
Cash at end of period$75.6M$90.4M$40M$66.4M$53.4M
Operating cash flow-$-50.89M-$-58.52M-$-88.51M-$-52.17M-$-27.53M
Capital expenditure-$-6.72M-$-15.56M-$-24.55M-$-34.27M-$-6.73M
Free cash flow-$-57.61M-$-74.08M-$-113.06M-$-86.43M-$-34.26M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Establishment Labs Holdings Inc.

        Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive plastic surgery. The company is primarily recognized for its silicone gel-filled breast implants, sold under the Motiva Implants brand. Among these are the Motiva Ergonomix and Motiva Ergonomix2, which are distinctive, gravity-sensitive, round, soft silicone-gel-filled implants. Furthermore, Establishment Labs provides the Motiva Flora Tissue Expander for breast tissue and distributes the Puregraft range of products, utilized for the harvesting and redistribution of autologous adipose tissue. The firm markets its offerings across Europe, Latin America, the Asia-Pacific region, and other global markets, leveraging both a direct sales force and exclusive distributors. Founded in 2004, Establishment Labs has its main office situated in Alajuela, Costa Rica.

        CEO
        Fillipo Peter Caldini
        Employees
        1K
        Beta
        1.07

        Explore

        Frequently asked questions

        What is the intrinsic value of Establishment Labs Holdings Inc. (ESTA)?

        Establishment Labs Holdings Inc. (ESTA) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ESTA undervalued?

        ESTA trades at a price of $69.14 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.